ERBB2 and breast neoplasm: By week 24, 65% (24/37) of the animals in the MMTV-neu/IL-1R8−/− group developed breast tumors compared to 95% (26/27) in the group of MMTV-neu/IL-1R8+/+ mice (P = 0.0003).